Today's undervalued category is tomorrow's over-crowded sector, yet newcomers are emerging. This panel will examine issues, opportunities, and approaches to dealmaking among an emerging generation of undervalued therapeutic categories. How is large pharma navigating business development in crowded categories that are seeing newcomers climb up the ranks? What are the approaches among therapeutic areas that have been both in-demand and approached with caution, and today are somewhere new? What positioning strategies are working and what are the pitfalls? Experts in private equity, banking, large pharma, and biotech will share case studies, insights, and predictions as well as offer practical advice.